Lantheus buys radiopharma CDMO
Lantheus, a Massachusetts-based developer of radiopharmaceuticals, has agreed to acquire the radiopharma contract development and manufacturing organization (CDMO) Evergreen Theragnostics. Lantheus will pay $250 million up front and up to $750 million in milestone payments. With the deal, Lantheus gains Evergreen’s Octevy, a diagnostic for certain neuroendocrine tumors that could complement a drug Lantheus is developing. Lantheus recently said it would pay $350 million to buy the positron emission tomography tracer developer Life Molecular Imaging.
Authors
- Rowan Walrath
Publication Details
- Journal
- C&EN Global Enterprise
- Published
- 2025-02-10
- DOI
- https://doi.org/10.1021/cen-10303-buscon15
- Primary Topic
- Chemical Reactions and Isotopes
- Type
- article
- Field-Weighted Citation Impact
- 0.00